Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543763 · ClinicalTrials.gov registry record · Phase 1
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
A Phase 1 study, sponsored by Pamela Munster.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT01543763: Completed Phase 1 study, sponsored by Pamela Munster.
NCT01543763 is a Phase 1 study that has completed, run by Pamela Munster. The registered enrollment target is 90 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01543763, a Phase 1 study, has completed, sponsored by Pamela Munster.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
Primary Outcome
A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related
Interventions
- DRUG PZP115891, PCI-24781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2012-06-25 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
What the finished NCT01543763 record still lists
NCT01543763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 1 intervention - of which PZP115891, PCI-24781 is the first listed.
NCT01543763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01543763 about?
NCT01543763 is a clinical study titled "Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors". This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
What is the current status of trial NCT01543763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2012-06-25. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT01543763?
The interventions under investigation include: PZP115891, PCI-24781 (DRUG).
Who is sponsoring clinical trial NCT01543763?
This trial is sponsored by Pamela Munster, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01543763's enrollment target sits among peer trials
90 628th of 2000 higher than 1,352 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI